GlassScriptPhysician profile
Jessica Daniel
NPI 1497595243
$731.84
in general payments reported to CMS, 2019-2025
25 companies · $594 in 2025
The $594 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $138 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682 · Education: $49.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.85 |
| Education | $49.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $113.38 | 2024-2025 | Jakafi, Monjuvi |
| Genentech USA, INC. | $69.39 | 2024-2025 | Polivy, Venclexta, Itovebi |
| Genmab U.S., INC. | $39.70 | 2024-2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $34.79 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $34.14 | 2025 | Opdivo |
| Janssen Biotech, INC. | $33.99 | 2025 | Rybrevant, Erleada, Balversa |
| Takeda Pharmaceuticals U.S.A., INC. | $27.25 | 2025 | Ninlaro |
| Aveo Pharmaceuticals, INC. | $26.75 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.17 | 2025 | |
| Abbvie INC. | $26.05 | 2024 | |
| Exelixis INC. | $25.61 | 2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $24.36 | 2025 | Keytruda, Welireg |
| Beone Medicines USA, INC. | $23.54 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $22.82 | 2024 | Somatuline Depot, Onivyde |
| Beigene USA, INC. | $22.66 | 2024 | Tevimbra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $22.42 | 2025 | Orgovyx |
| Daiichi Sankyo INC. | $20.76 | 2025 | Datroway |
| Adaptive Biotechnologies Corporation | $20.75 | 2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $19.93 | 2025 | Libtayo |
| Coherus Oncology, INC. | $19.89 | 2025 | Udenyca |
| Glaxosmithkline, LLC. | $18.63 | 2025 | Ojjaara |
| Eisai INC. | $18.20 | 2025 | |
| Celgene Corporation | $16.26 | 2025 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $15.95 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Pharmaand Gmbh | $8.45 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.